(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
2024 Eurovision winner Nemo returns trophy over Israel's participation - 2Finding the Force of Mentorship: Self-awareness Through Direction
- 3Improving as a Cook: Culinary Experiences in the Kitchen
- 4Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- 5Ten Awesome Authentic Realities That Will Leave You Interested
- Instructions to Pick the Best Album Rates for Your Investment funds
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- Israel approves 19 new West Bank settlements in major annexation push
- Bomb blast in packed Nigerian mosque kills five
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Experience Arranging: Planning for Epic Excursions
- Vote in favor of your Number one natural product
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
